Multicenter evaluation of a novel ROS1 immunohistochemistry assay (SP384) for detection of ROS1 rearrangements in a large cohort of lung adenocarcinoma patients.
Fiche publication
Date publication
avril 2019
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VIGNAUD Jean-Michel, Pr BIBEAU Frédéric
Tous les auteurs :
Hofman V, Rouquette I, Long-Mira E, Piton N, Chamorey E, Heeke S, Vignaud JM, Yguel C, Mazières J, Lepage AL, Bibeau F, Begueret H, Lassalle S, Lalvée S, Zahaf K, Benzaquen J, Poudenx M, Marquette CH, Sabourin JC, Ilié M, Hofman P
Lien Pubmed
Résumé
The detection of a ROS1 rearrangement in advanced and metastatic lung adenocarcinoma (LUAD) lead to a targeted treatment with tyrosine kinase inhibitors, with favorable progression-free survival and overall survival of the patients. Thus, it is mandatory to screen for the ROS1 rearrangement in all these patients. ROS1 rearrangements can be detected using break-apart fluorescence in situ hybridization (FISH), which is the "gold standard"; however, ROS1 immunohistochemistry (IHC) can be used as a screening test since it is widely available, easy and rapid to perform, and cost-effective.
Mots clés
D4D6, FISH, ROS1, SP384, immunohistochemistry, lung adenocarcinoma
Référence
J Thorac Oncol. 2019 Apr 15;: